Combining B7‐H3 blocking mAbs and crizotinib appeared to exhibit synergistic therapeutic effect in vivo, suggesting that, as a combinational treatment approach, blocking B7‐H3 and c‐Met signaling module may enhance the therapeutic efficiency in cancer treatment. This evidence concerns the gene MET and cancer.